Related Experiment Video

Updated: Oct 22, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.5K

Survival Rates and Prognostic Factors in Patients with Coronavirus Disease 2019: A Registry-Based Retrospective

Fatemeh Shahbazi1,2, Manoochehr Karami1,3, Mohammad Mirzaei4

  • 1Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.

Journal of Research in Health Sciences
|September 1, 2021
PubMed

Insights

This study identified key risk factors for COVID-19 mortality in Iran. Elderly individuals, males, and those with comorbidities faced a higher risk of death, highlighting the need for targeted interventions.

Area of Science:

  • Epidemiology
  • Infectious Diseases
  • Public Health

Background:

  • Coronavirus disease 2019 (COVID-19) is a contagious illness with incompletely understood survival rates and prognostic factors.
  • Understanding these factors is crucial for effective public health strategies and patient management.

Purpose of the Study:

  • To identify risk factors associated with survival among COVID-19 patients.
  • To analyze prognostic factors influencing COVID-19 outcomes in Hamadan province, Iran.

Main Methods:

  • Retrospective cohort study conducted in Hamadan province, Iran (February 20 - September 20, 2020).
  • Inclusion of patients referred to provincial hospitals, with follow-up from symptom onset to death.
  • Statistical analysis using Kaplan-Meier method, Flemington-Harrington test, and Cox regression.

Main Results:

  • Overall survival rates at 1, 5, 10, 20, 30, and 49 days were 99.57%, 95.61%, 91.15%, 87.34%, 86.91%, and 86.74%, respectively.
  • Survival time was significantly associated with age, gender, travel history to contaminated areas, co-morbidities, neoplasms, chronic diseases, and hospital units.

Conclusions:

  • Elderly individuals, males, and patients with comorbidities exhibited a significantly higher risk of mortality from COVID-19.
  • Targeted attention and interventions for these high-risk groups are essential to mitigate COVID-19 incidence and consequences.
Abstract

Keywords:
COVID-19EpidemiologyIranMortalitySurvival

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.4K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

442

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
481
Actuarial Approach01:20

Actuarial Approach

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
159
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
351
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
218
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
16.9K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
311